• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

GlaxoSmithKline extends JP Garnier’s contract

GlaxoSmithKline plc today announces that Chief Executive Officer Dr. JP Garnier’s contract has been extended to May 2008. Dr. Garnier’s contract was set to expire in October 2007 upon his 60th birthday.

Sir Christopher Gent, Chairman, GlaxoSmithKline said:

“I am delighted that JP has agreed to an extension of his contract and will continue to lead GSK for the next two years. This will maintain momentum for GSK, in what will be an important and exciting period for the pipeline and, during this period, will enable the Board to complete the process for appointing his successor.”

Dr. JP Garnier said:
“I believe that the next two years will see further confirmation of GSK’s strong and innovative pipeline, with many significant filings and launches of new medicines and vaccines. I am proud to have the opportunity to continue leading GSK through this very important period.”

GlaxoSmithKline

• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• New seasonal and perennial rhinitis intranasal treatment submitted for U.S....
  
• GSK Announces US Government Purchase of Relenza® for State Stockpiles
  
• Adolor’s complete response to approvable letter for Entereg® alvimopan ...
  
• GlaxoSmithKline extends JP Garnier’s contract
  
• New Bonviva® quarterly injection approved in Europe for postmenopausal osteoporosis
  
• New data in Lancet confirm potential to eliminate Lymphatic Filariasis
  
• Rotarix : First vaccine against rotavirus available in Europe
  
• Dr Tachi Yamada to retire Dr Moncef Slaoui appointed successor as Chairman of R&D
  
• GlaxoSmithKline initiates trial of Tykerb lapatinib in patients with ErbB2-overexpressing breast..